Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin.

Suppr

超能文献

作者信息

Karim A, Lawlor F, Black M M

出版信息

Clin Exp Dermatol. 2004 May;29(3):317-8. doi: 10.1111/j.1365-2230.2004.01518.x.

DOI:10.1111/j.1365-2230.2004.01518.x

PMID:15115524

Abstract

摘要

相似文献

Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin.

Clin Exp Dermatol. 2004 May;29(3):317-8. doi: 10.1111/j.1365-2230.2004.01518.x.

Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulin.

Br J Dermatol. 2005 Sep;153(3):650-2. doi: 10.1111/j.1365-2133.2005.06710.x.

Beneficial effect of granulocyte-colony stimulating factor in scleromyxoedema associated with severe idiopathic neutropenia.

Br J Dermatol. 1996 Oct;135(4):626-9.

Intravenous immunoglobulins control scleromyxoedema.

Ann Rheum Dis. 2002 Jan;61(1):59-61. doi: 10.1136/ard.61.1.59.

Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin.

J Eur Acad Dermatol Venereol. 2007 Apr;21(4):553-4. doi: 10.1111/j.1468-3083.2006.01951.x.

Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulins.

J Eur Acad Dermatol Venereol. 2005 Jul;19(4):462-5. doi: 10.1111/j.1468-3083.2005.01134.x.

Arndt-Gottron scleromyxoedema: successful therapy with intravenous immunoglobulins.

Br J Dermatol. 2007 Nov;157(5):1058-60. doi: 10.1111/j.1365-2133.2007.08169.x. Epub 2007 Sep 13.

Koebner phenomenon due to scratch test in scleromyxoedema.

Br J Dermatol. 2001 Aug;145(2):306-8. doi: 10.1046/j.1365-2133.2001.04321.x.

Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin.

Br J Dermatol. 2003 Dec;149(6):1276-81. doi: 10.1111/j.1365-2133.2003.05682.x.

Scleroderma-like manifestation in a patient with primary systemic amyloidosis: response to high-dose intravenous immunoglobulin and plasma exchange.

Yonsei Med J. 2006 Oct 31;47(5):737-40. doi: 10.3349/ymj.2006.47.5.737.

引用本文的文献

Scleromyxedema: a case report and review of the literature.

Case Rep Dermatol. 2013 Jun 11;5(2):168-75. doi: 10.1159/000353178. Print 2013 May.

Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

J Clin Immunol. 2007 May;27(3):233-45. doi: 10.1007/s10875-007-9088-9. Epub 2007 Mar 11.

[Marked improvement in scleromyxedema with high-dose intravenous immunoglobulin].

Hautarzt. 2007 Jun;58(6):525-8. doi: 10.1007/s00105-006-1261-1.

[Scleromyxedema].

Hautarzt. 2006 Apr;57(4):326-7. doi: 10.1007/s00105-006-1113-z.

Clinical uses of intravenous immunoglobulin.

Clin Exp Immunol. 2005 Oct;142(1):1-11. doi: 10.1111/j.1365-2249.2005.02834.x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Successful treatment of scleromyxoedema with high dose intravenous immunoglobulin.

Clin Exp Dermatol. 2004 May;29(3):317-8. doi: 10.1111/j.1365-2230.2004.01518.x.

Dementia associated with scleromyxoedema reversed by high-dose intravenous immunoglobulin.

Br J Dermatol. 2005 Sep;153(3):650-2. doi: 10.1111/j.1365-2133.2005.06710.x.

Beneficial effect of granulocyte-colony stimulating factor in scleromyxoedema associated with severe idiopathic neutropenia.

Br J Dermatol. 1996 Oct;135(4):626-9.

Intravenous immunoglobulins control scleromyxoedema.

Ann Rheum Dis. 2002 Jan;61(1):59-61. doi: 10.1136/ard.61.1.59.

Successful therapy of scleromyxoedema Arndt-Gottron with low-dose intravenous immunoglobulin.

J Eur Acad Dermatol Venereol. 2007 Apr;21(4):553-4. doi: 10.1111/j.1468-3083.2006.01951.x.

Tumorous variant of scleromyxedema. Successful therapy with intravenous immunoglobulins.

J Eur Acad Dermatol Venereol. 2005 Jul;19(4):462-5. doi: 10.1111/j.1468-3083.2005.01134.x.

Arndt-Gottron scleromyxoedema: successful therapy with intravenous immunoglobulins.

Br J Dermatol. 2007 Nov;157(5):1058-60. doi: 10.1111/j.1365-2133.2007.08169.x. Epub 2007 Sep 13.

Koebner phenomenon due to scratch test in scleromyxoedema.

Br J Dermatol. 2001 Aug;145(2):306-8. doi: 10.1046/j.1365-2133.2001.04321.x.

Scleromyxoedema: treatment of cutaneous and systemic manifestations with high-dose intravenous immunoglobulin.

Br J Dermatol. 2003 Dec;149(6):1276-81. doi: 10.1111/j.1365-2133.2003.05682.x.

Scleroderma-like manifestation in a patient with primary systemic amyloidosis: response to high-dose intravenous immunoglobulin and plasma exchange.

Yonsei Med J. 2006 Oct 31;47(5):737-40. doi: 10.3349/ymj.2006.47.5.737.

引用本文的文献

Scleromyxedema: a case report and review of the literature.

Case Rep Dermatol. 2013 Jun 11;5(2):168-75. doi: 10.1159/000353178. Print 2013 May.

Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

J Clin Immunol. 2007 May;27(3):233-45. doi: 10.1007/s10875-007-9088-9. Epub 2007 Mar 11.

[Marked improvement in scleromyxedema with high-dose intravenous immunoglobulin].

Hautarzt. 2007 Jun;58(6):525-8. doi: 10.1007/s00105-006-1261-1.

[Scleromyxedema].

Hautarzt. 2006 Apr;57(4):326-7. doi: 10.1007/s00105-006-1113-z.

Clinical uses of intravenous immunoglobulin.

Clin Exp Immunol. 2005 Oct;142(1):1-11. doi: 10.1111/j.1365-2249.2005.02834.x.